Nplate and Vectibix Could Contribute to Amgen’s Revenue Growth in 2017
In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.
In 1Q17, Kyprolis generated revenues of ~$190 million compared to $154 million in 1Q16.
In 2016, Amgen’s (AMGN) Neulasta generated revenues close to $4.6 billion, which was a slight drop from its 2015 net sales of ~$4.7 billion.
Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.
Amgen’s (AMGN) Xgeva was launched commercially in 2010 and is marketed primarily in the US and Europe. The drug crossed the $1 billion annual revenue mark in 2013.
According to a March 2016 report by QuintilesIMSHealth, the biologics market is estimated to reach $390 billion by 2020.
In 1Q17, Neupogen generated revenues of ~$148 million, a significant drop from the drug’s 1Q16 revenues of ~$213 million.
In 1Q17, Amgen’s (AMGN) Repatha witnessed quarter-over-quarter growth in sales volume of ~14% and 28% in the US and Europe, respectively.
In 1Q17, Amgen’s (AMGN) Blincyto reported revenues of ~$34 million, which is equivalent to year-over-year sales growth of 26%.
Enbrel, Neulasta, and Epogen are among Amgen’s (AMGN) major revenue-generating drugs, each with annual sales in excess of $1 billion. Enbrel and Neulasta together accounted for ~46% of Amgen’s 2016 revenues.
Zoetis (ZTS) expects to generate savings of over $300 million in 2017 through its operational efficiency program.
In 1Q17, Zoetis (ZTS) managed to earn $615 million as revenues from international markets, which represents a YoY growth of around 8%.
In 1Q17, Zoetis’s (ZTS) Companion Animal Health segment saw revenues of ~$517 million, which represents a YoY operational growth of around 12%.
In 1Q17, Zoetis’s (ZTS) dermatology portfolio reported revenues of ~$57 million, driven by the steady adoption of Cytopoint and Apoquel.
In 1Q17, Zoetis’s key livestock brands Excede anti-infective, Excenel RTU, Fostera, and Bovi-Shield witnessed label expansions.
Zoetis (ZTS) has adopted a targeted R&D strategy that has resulted in multiple new product launches.
Zoetis (ZTS) expects the animal health market to grow YoY in the range of 5%–6% in 2017.
Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.
During its 1Q17 earnings conference call, Alexion Pharmaceuticals (ALXN) reiterated that its drug Soliris’s 2017 revenue would fall in the range of $3.0 billion–$3.1 billion.
While Soliris is expected to continue to be a key revenue driver for Alexion Pharmaceuticals (ALXN) in 2017, the company anticipates an increasingly negative impact on Solaris’s 2017 sales.